-
公开(公告)号：US10259856B2
公开(公告)日：2019-04-16
申请号：US14686176
申请日：2015-04-14
申请人： Novo Nordisk A/S
发明人： Peter Madsen , Thomas Boerglum Kjeldsen , Thomas Hoeg-Jensen , Palle Jakobsen , Tina Moeller Tagmose , Tine Glendorf , Janos Tibor Kodra , Patrick William Garibay , Jacob Sten Petersen
摘要： Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
-
公开(公告)号：US20180140673A1
公开(公告)日：2018-05-24
申请号：US15849920
申请日：2017-12-21
申请人： Novo Nordisk A/S
发明人： Birgit Wieczorek , Tina Moeller Tagmose , Kristian Sass-Oerum , Birgitte Andersen , Joergen Olsen
CPC分类号： A61K38/1825 , A61K38/00 , A61K47/542 , C07K14/50
摘要： The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.
-
公开(公告)号：US10124039B2
公开(公告)日：2018-11-13
申请号：US15849920
申请日：2017-12-21
申请人： Novo Nordisk A/S
发明人： Birgit Wieczorek , Tina Moeller Tagmose , Kristian Sass-Oerum , Birgitte Andersen , Joergen Olsen
摘要： The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.
-
公开(公告)号：US09896496B2
公开(公告)日：2018-02-20
申请号：US15023872
申请日：2014-10-03
申请人： Novo Nordisk A/S
摘要： The present invention provides a novel derivative of an analogue of human insulin, useful for the treatment of diabetes.
-
公开(公告)号：US20150210747A1
公开(公告)日：2015-07-30
申请号：US14684863
申请日：2015-04-13
申请人： NOVO NORDISK A/S
发明人： Peter Madsen , Thomas B. Kjeldsen , Thomas Hoeg-Jensen , Palle Jakobsen , Tina Moeller Tagmose , Tine Glendorf , Janos Tibor Kodra , Patrick William Garibay , Jacob Sten Petersen
IPC分类号： C07K14/62
摘要： Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
摘要翻译： 对蛋白酶具有抗性的新型酰化胰岛素类似物可以有效地被肺或口服给药。 胰岛素类似物含有B25H和A14E或A14H。
-
公开(公告)号：US09045560B2
公开(公告)日：2015-06-02
申请号：US13973183
申请日：2013-08-22
申请人： Novo Nordisk A/S
发明人： Peter Madsen , Thomas Boerglum Kjeldsen , Thomas Hoeg-Jensen , Palle Jakobsen , Tina Moeller Tagmose , Tine Glendorf , Jaanos Tibor Kodra , Patrick William Garibay , Jacob Sten Petersen
摘要： Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
摘要翻译： 对蛋白酶具有抗性的新型酰化胰岛素类似物可以有效地被肺或口服给药。 胰岛素类似物含有B25H和A14E或A14H。
-
公开(公告)号：US08791236B2
公开(公告)日：2014-07-29
申请号：US14166148
申请日：2014-01-28
申请人： Novo Nordisk A/S
发明人： Caspar Christensen , Rune Severinsen , Anders Klarskov Petersen , Steffen Kidal , Claus U. Jessen , Peter Madsen , Henrik Valore , Tina Moeller Tagmose , Jan Lindy Soerensen
CPC分类号： C07K1/1077 , A61K47/54 , C07K14/605 , C07K14/62
摘要： A method for selectively acylating an amino group in a peptide or protein which has two or more reactive nucleophilic functional groups is described.
摘要翻译： 描述了选择性酰化具有两个或更多个反应性亲核官能团的肽或蛋白质中的氨基的方法。
-
公开(公告)号：US20140073564A1
公开(公告)日：2014-03-13
申请号：US13973183
申请日：2013-08-22
申请人： Novo Nordisk A/S
发明人： Peter Madsen , Thomas Boerglum Kjeldsen , Thomas Hoeg-Jensen , Palle Jakobsen , Tina Moeller Tagmose , Tine Glendorf , Jaanos Tibor Kodra , Patrick William Garibay , Jacob Sten Petersen
IPC分类号： C07K14/62
摘要： Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
摘要翻译： 对蛋白酶具有抗性的新型酰化胰岛素类似物可以有效地被肺或口服给药。 胰岛素类似物含有B25H和A14E或A14H。
-
公开(公告)号：US11471537B2
公开(公告)日：2022-10-18
申请号：US16500897
申请日：2018-04-04
申请人： Novo Nordisk A/S
发明人： Tina Moeller Tagmose , Peter Madsen , Thomas Boerglum Kjeldsen , Lone Pridal , Leonardo De Maria , Zhaosheng Lin , Zhe Wan , Yuanyuan Zhang , Lennart Lykke , Martin Werner Borchsenius Muenzel , Janos Tibor Kodra
摘要： This invention is in the field of protein conjugates. More specifically the invention relates to oligomer extended insulins with covalently attached Fc monomer polypeptides, for use in the treatment of a metabolic disorder or condition, and to methods of producing such oligomer extended insulin-Fc conjugates. The invention also relates to novel Fc fragments, to intermediate products, and to the use of such intermediate products in processes for the synthesis of the oligomer extended insulin-Fc conjugates of the invention. Finally the invention provides pharmaceutical compositions comprising the oligomer extended insulin-Fc conjugates of the invention, and relates to the use of such compositions for the treatment or prevention of medical conditions relating to metabolic disorders or conditions.
-
公开(公告)号：US20210393745A1
公开(公告)日：2021-12-23
申请号：US17284332
申请日：2019-10-09
申请人： Novo Nordisk A/S
发明人： Tina Moeller Tagmose , Peter Madsen , Thomas Boerglum Kjeldsen , Lone Pridal , Zhaosheng Lin , Yuanyuan Zhang , Zhe Wan
IPC分类号： A61K38/28 , A61K47/22 , C07D207/46 , A61K47/68 , A61P3/10
摘要： This invention is in the field of protein conjugates. More specifically the invention relates to oligomer extended insulins with covalently attached Fc monomer polypeptides, for use in the treatment of a metabolic disorder or condition, and to methods of producing such oligomer extended insulin-Fc conjugates. The invention also relates to a novel Fc fragment, to intermediate products, and to the use of such intermediate products in processes for the synthesis of the oligomer extended insulin-Fc conjugates of the invention. Finally the invention provides pharmaceutical compositions comprising the oligomer extended insulin-Fc conjugates of the invention, and relates to the use of such compositions for the treatment or prevention of medical conditions relating to metabolic disorders or conditions.
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.024 秒)
